 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, UCD19 CAR T Cells / University of Colorado
Use of CD19 CAR-T Cells in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission: Preliminary Outcomes from a Phase I Clinical Trial () - Dec 7, 2024 - Abstract #ASH2024ASH_7956;
Incorporation of blinatumomab and/or inotuzumab in CR1 may mitigate the negative prognostic significance of MRD, however it is unclear if intensity of standard post-remission therapy can be safely reduced without compromising outcomes...We designed a phase I clinical trial to determine safety and tolerability of UCD19 CAR-T cell therapy for adults with B-ALL in MRD+ CR1 who are at high risk for relapse.Methods : Eligible patients include adults (?18yo) with B-ALL in CR1 after induction therapy, with MRD positivity by either flow cytometry or NGS (Clonoseq)...Longer follow-up is needed to determine if remissions remain durable, and to determine the relationship between functional persistence (as measured by B-cell aplasia) and remission durability. Enrollment is ongoing at DL2.
- | UCD19 CAR T Cells / University of Colorado
Trial completion date: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - May 3, 2024
P1, N=11, Active, not recruiting, Sponsor: University of Colorado, Denver
Enrollment is ongoing at DL2. Trial completion date: Dec 2023 --> Dec 2024
- | UCD19 CAR T Cells / University of Colorado
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (clinicaltrials.gov) - Dec 31, 2023
P1/2, N=50, Recruiting, Sponsor: University of Colorado, Denver
- | UCD19 CAR T Cells / University of Colorado
Trial primary completion date: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Oct 1, 2023
P1, N=11, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Dec 2023 --> Dec 2024 Trial primary completion date: Dec 2023 --> Mar 2023
- | UCD19 CAR T Cells / University of Colorado
Trial primary completion date: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Jul 7, 2023
P1, N=11, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2023 --> Mar 2023 Trial primary completion date: Dec 2022 --> Dec 2023
- | UCD19 CAR T Cells / University of Colorado
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy, Minimal residual disease: UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1 (clinicaltrials.gov) - Jul 7, 2023
P1, N=14, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Jul 2027 | Initiation date: Dec 2023 --> Jul 2023 | Trial primary completion date: Apr 2025 --> Jul 2025
- | UCD19 CAR T Cells / University of Colorado
Trial initiation date, CAR T-Cell Therapy, Minimal residual disease: UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1 (clinicaltrials.gov) - Jan 31, 2023
P1, N=14, Not yet recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Jul 2027 | Initiation date: Dec 2023 --> Jul 2023 | Trial primary completion date: Apr 2025 --> Jul 2025 Initiation date: Dec 2022 --> Dec 2023
- | UCD19 CAR T Cells / University of Colorado
New P1 trial, CAR T-Cell Therapy, Minimal residual disease: UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1 (clinicaltrials.gov) - Sep 10, 2022
P1, N=14, Not yet recruiting, Sponsor: University of Colorado, Denver
- | UCD19 CAR T Cells / University of Colorado
Enrollment closed, Enrollment change: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Sep 2, 2022
P1, N=11, Active, not recruiting, Sponsor: University of Colorado, Denver
Initiation date: Dec 2022 --> Dec 2023 Recruiting --> Active, not recruiting | N=20 --> 11
- | UCD19 CAR T Cells / University of Colorado
Trial completion date: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Aug 12, 2022
P1, N=20, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | N=20 --> 11 Trial completion date: Dec 2022 --> Dec 2023
- | UCD19 CAR T Cells / University of Colorado
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (clinicaltrials.gov) - Aug 19, 2021
P1/2, N=50, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Dec 2022 --> Dec 2023 Trial completion date: Jul 2021 --> Jul 2026 | Trial primary completion date: Jun 2021 --> Jun 2026
- | UCD19 CAR T Cells / University of Colorado
Trial completion date, Trial primary completion date: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Jun 23, 2021
P1, N=20, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Jul 2021 --> Jul 2026 | Trial primary completion date: Jun 2021 --> Jun 2026 Trial completion date: Mar 2024 --> Dec 2022 | Trial primary completion date: Mar 2024 --> Dec 2022
- | UCD19 CAR T Cells / University of Colorado
Enrollment open, CAR T-Cell Therapy: UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (clinicaltrials.gov) - Mar 22, 2021
P1/2, N=50, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Mar 2024 --> Dec 2022 | Trial primary completion date: Mar 2024 --> Dec 2022 Not yet recruiting --> Recruiting
- | UCD19 CAR T Cells / University of Colorado
Enrollment open: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Jun 18, 2020
P1, N=20, Recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | UCD19 CAR T Cells / University of Colorado
Trial initiation date: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Apr 27, 2020
P1, N=20, Not yet recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Initiation date: Mar 2020 --> Sep 2020
- | UCD19 CAR T Cells / University of Colorado
New P1 trial: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov) - Jan 27, 2020
P1, N=20, Not yet recruiting, Sponsor: University of Colorado, Denver